TLDR
- Codexis (CDXS) exceeded Q4 EPS projections by $0.10, delivering $0.11 against analyst consensus of $0.01
- Q4 revenue reached $38.9 million, representing an 81% year-over-year increase and surpassing the $35.83 million forecast
- A Technology Transfer Agreement with Merck worth $37.8 million powered the quarterly revenue acceleration
- Annual 2025 net loss contracted to $44.0 million compared to $65.3 million in 2024
- Revenue outlook for 2026 established at $72–$76 million; available cash supports operations through 2027
Codexis delivered its Q4 and complete 2025 financial results on March 11, 2026, surpassing Wall Street projections across earnings and revenue metrics. Shares responded with a 2.4% gain to reach $1.27.
Quarterly EPS arrived at $0.11, exceeding consensus expectations of $0.01 by $0.10. The company generated $38.9 million in revenue during the quarter, outperforming the $35.83 million analyst estimate while climbing 81% from the $21.5 million posted in Q4 2024.
A Technology Transfer Agreement with Merck valued at $37.8 million, finalized during Q4, served as the primary catalyst behind the revenue performance.
Across the full year, total revenue expanded 19% to $70.4 million versus $59.3 million in 2024. Product gross margin strengthened to 64% compared to 56% in the previous year.
Annual net loss compressed to $44.0 million, or $0.50 per share, against a $65.3 million loss, or $0.89 per share, recorded in 2024. The fourth quarter turned profitable with net income of $9.6 million, contrasting with a $10.4 million loss during the same period one year prior.
SG&A expenses declined to $47.1 million for the year from $55.1 million in 2024, reflecting reductions in stock-based compensation and legal costs. R&D investment increased to $52.3 million from $46.3 million.
The annual results incorporated $3.4 million in one-time restructuring expenses connected to a workforce reduction implemented in November 2025.
Cash Position and Guidance
Codexis closed 2025 holding $78.2 million in cash, cash equivalents and short-term investments. Management indicates this liquidity provides operational runway extending through the conclusion of 2027.
The company has established 2026 revenue guidance ranging from $72 million to $76 million.
Regarding business development, Codexis maintains active engagement with more than 40 companies spanning 55 potential opportunities. CEO Alison Moore highlighted that client discussions have evolved from feasibility testing phases toward comprehensive contract negotiations.
The company executed a lease agreement for a GMP facility with kilogram-scale manufacturing capabilities. Construction retrofit work is scheduled to commence during the second half of 2026, targeting full production capacity by the close of 2027.
Codexis established an agreement with Axolabs — marking its third CDMO partnership — to assess its ECO Synthesis technology within Axolabs’ manufacturing infrastructure.
Analyst Sentiment and Institutional Activity
Analyst sentiment continues to trend bearish despite the positive earnings results. Weiss Ratings maintained a “Sell” rating on January 21, while the MarketBeat consensus stands at “Sell.”
Shares trade nearer to the 52-week low of $0.96 compared to the high of $3.87, with market capitalization standing at $114.7 million. The 50-day moving average rests at $1.39 while the 200-day sits at $1.90.
Institutional investors have expanded positions recently. Millennium Management increased its stake by 3,376.5% during Q3. Renaissance Technologies raised its holdings by 137.5% in Q4. Institutional ownership comprises 78.54% of outstanding shares.
The company aims to secure a licensing agreement with a major pharmaceutical partner during the second half of 2026 and intends to unveil stereoisomer control data at the 2026 TIDES USA annual meeting.
